Table 1. Characteristics of the study cohort.
| Characteristic | 2.5mg Qday Starting Dose (n=170) |
5mg Qday Starting Dose (n=154) |
p |
|---|---|---|---|
| Age (yrs) | 28.9 ± 6.1 | 29.3 ± 5.9 | 0.52 |
| Race or ethnic group | 0.22 | ||
| White | 18 (11.1) | 27 (18.9) | |
| Black | 93 (57.4) | 81 (56.6) | |
| Hispanic | 49 (30.3) | 35 (24.5) | |
| Other | 2 (1.3) | 0 (0.0) | |
| Nulliparous | 47 (27.7) | 44 (28.6) | 0.85 |
| Public Insurance | 139 (86.3) | 117 (81.8) | 0.28 |
| Smoking | 28 (16.5) | 33 (21.4) | 0.25 |
| Chronic hypertension | 23 (13.5) | 27 (17.5) | 0.40 |
| GDM in prior pregnancy | 31 (18.2) | 27 (17.5) | 0.87 |
| Neonatal macrosomia in prior pregnancy |
23 (13.5) | 21 (13.6) | 0.98 |
| Pre-pregnancy BMI (kg/m2) |
34.5 ± 8.1 | 36.5 ± 9.3 | 0.04 |
| Obese (≥30.0) | 116 (69.9) | 120 (79.5) | 0.05 |
| Gestational age at diagnosis of GDM |
25.8 ± 4.1 | 25.7 ± 4.7 | 0.87 |
| 50-g Glucose Challenge Test (screening test), 1 hr value (mg/dL) |
187 ± 32 | 194 ± 38 | 0.08 |
| 3 hr oral GTT (diagnostic test) (mg/dL) |
|||
| Fasting | 107 ± 15 | 116 ± 24 | <0.01 |
| 1 hour | 203 ± 29 | 205 ± 32 | 0.76 |
| 2 hour | 177 ± 28 | 185 ± 29 | 0.07 |
| 3 hour | 138 ± 33 | 131 ± 31 | 0.24 |
| Gestational age at glyburide initiation |
31.3 ± 7.5 | 30.8 ± 6.0 | 0.51 |
| Highest fasting blood sugar upon starting glyburide |
121 ± 21 | 126 ± 25 | 0.24 |
| Failed glyburide | 4 (3.1) | 5 (4.0) | 0.67 |
| Gestational age at delivery | 38.2 ± 2.0 | 37.8 ± 2.8 | 0.08 |
| Total gestational weight gain (kg) |
13.3 ± 10.3 | 13.4 ± 10.3 | 0.87 |
| Gestational Weight Gain Less than IOM Recommendations |
31 (18.7%) | 31 (20.5%) | 0.12 |
| Within IOL Recommendations |
38 (22.9%) | 21 (13.9%) | |
| More than IOL Recommendations |
97 (58.4%) | 99 (65.6%) |
BMI, body mass index; GTT, glucose tolerance test; GDM, gestational diabetes mellitus Data are mean +/− standard deviation or n (%), unless otherwise specified